
## Sylvie Mavel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3077168/publications.pdf Version: 2024-02-01



SVIVIE MAVEL

#	Article	IF	CITATIONS
1	SHR/NCrl rats as a model of ADHD can be discriminated from controls based on their brain, blood, or urine metabolomes. Translational Psychiatry, 2021, 11, 235.	2.4	3
2	Optimization of Sample Preparation for Metabolomics Exploration of Urine, Feces, Blood and Saliva in Humans Using Combined NMR and UHPLC-HRMS Platforms. Molecules, 2021, 26, 4111.	1.7	31
3	Maternal Rat Metabolomics: Amniotic Fluid and Placental Metabolic Profiling Workflows. Journal of Proteome Research, 2021, 20, 3853-3864.	1.8	3
4	Deletion of Mocos induces xanthinuria with obstructive nephropathy and major metabolic disorders in mice. Kidney360, 2021, 2, 10.34067/KID.0001732021.	0.9	2
5	Analytical Methodology for a Metabolome Atlas of Goat's Plasma, Milk and Feces Using 1H-NMR and UHPLC-HRMS. Metabolites, 2021, 11, 681.	1.3	0
6	Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS. Talanta, 2019, 195, 593-598.	2.9	33
7	Identification of metabolic pathway disturbances using multimodal metabolomics in autistic disorders in a Middle Eastern population. Journal of Pharmaceutical and Biomedical Analysis, 2018, 152, 57-65.	1.4	49
8	The Metabolic Disturbances of Motoneurons Exposed to Glutamate. Molecular Neurobiology, 2018, 55, 7669-7676.	1.9	12
9	Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S. European Journal of Medicinal Chemistry, 2018, 144, 201-210.	2.6	17
10	Validation of metabolomics analysis of human perilymph fluid using liquid chromatography-mass spectroscopy. Hearing Research, 2018, 367, 129-136.	0.9	22
11	Wildtype motoneurons, ALSâ€Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia, 2017, 65, 592-605.	2.5	62
12	Workflow methodology for rat brain metabolome exploration using NMR, LC–MS and GC–MS ana GC–MS analytical platforms. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 270-278.	1.4	26
13	NSC-34 Motor Neuron-Like Cells Are Unsuitable as Experimental Model for Glutamate-Mediated Excitotoxicity. Frontiers in Cellular Neuroscience, 2016, 10, 118.	1.8	41
14	Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. European Journal of Neurology, 2016, 23, 346-353.	1.7	31
15	Liquid chromatography–high-resolution mass spectrometry-based cell metabolomics: Experimental design, recommendations, and applications. TrAC - Trends in Analytical Chemistry, 2016, 75, 118-128.	5.8	44
16	Metabolomics Study of Urine in Autism Spectrum Disorders Using a Multiplatform Analytical Methodology. Journal of Proteome Research, 2015, 14, 5273-5282.	1.8	98
17	Analytical methodology for metabolomics study of adherent mammalian cells using NMR, GC-MS and LC-HRMS. Analytical and Bioanalytical Chemistry, 2015, 407, 8861-8872.	1.9	39
18	The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development. Current Medicinal Chemistry, 2014, 21, 3551-3575.	1.2	132

Sylvie Mavel

#	Article	IF	CITATIONS
19	Design of α7 nicotinic acetylcholine receptor ligands in quinuclidine, tropane and quinazoline series. Chemistry, molecular modeling, radiochemistry, inÂvitro and in rats evaluations of a [18F] quinuclidine derivative. European Journal of Medicinal Chemistry, 2014, 82, 214-224.	2.6	18
20	Combined <sup>1</sup> H-NMR and <sup>1</sup> H– <sup>13</sup> C HSQC-NMR to improve urinary screening in autism spectrum disorders. Analyst, The, 2014, 139, 3460-3468.	1.7	46
21	Untargeted <sup>1</sup> H-NMR metabolomics in CSF. Neurology, 2014, 82, 1167-1174.	1.5	42
22	Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry. Journal of Proteome Research, 2013, 12, 3746-3754.	1.8	77
23	Aromatic fluoro-de-triazenation with boron trifluoride diethyl etherate under non-protic acid conditions. Journal of Fluorine Chemistry, 2013, 147, 5-9.	0.9	14
24	1H–13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta, 2013, 114, 95-102.	2.9	79
25	3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and analogues, novel Flaviviridae inhibitors. European Journal of Medicinal Chemistry, 2013, 64, 448-463.	2.6	42
26	GC-MS-based urine metabolic profiling of autism spectrum disorders. Analytical and Bioanalytical Chemistry, 2013, 405, 5291-5300.	1.9	109
27	<sup>18</sup> F-Labeled Aryl-Tracers through Direct Introduction of [ <sup>18</sup> F]fluoride into Electron-Rich Arenes. Current Organic Chemistry, 2013, 17, 2921-2935.	0.9	3
28	QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT). Bioorganic and Medicinal Chemistry, 2012, 20, 1388-1395.	1.4	10
29	Effects of Two <i>N</i> -arylpiperazinylmethylpyrazolo [1,5- <i>d</i> ][1,2,4]triazine Derivatives in Pain and Antidepressant Tests in Mice. Journal of Pharmacy and Pharmacology, 2011, 49, 1019-1024.	1.2	5
30	Nucleophilic fluorination of alkynyliodonium salts by alkali metal fluorides: access to fluorovinylic compounds. Tetrahedron, 2011, 67, 3434-3439.	1.0	19
31	Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands. Bioorganic and Medicinal Chemistry, 2010, 18, 236-241.	1.4	12
32	3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT). Bioorganic and Medicinal Chemistry, 2010, 18, 7659-7667.	1.4	25
33	Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging. Bioorganic and Medicinal Chemistry, 2008, 16, 9050-9055.	1.4	7
34	(E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter. Nuclear Medicine and Biology, 2007, 34, 967-971.	0.3	5
35	Synthesis andex vivo evaluation of aza-trozamicol analogs as SPECT radiotracers for exploration of the vesicular acetylcholine transporter. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 139-145.	0.5	3
36	Oneâ€step radiosynthesis of [ <sup>18</sup> F]LBTâ€999: a selective radioligand for the visualization of the dopamine transporter with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 716-723.	0.5	29

Sylvie Mavel

#	Article	IF	CITATIONS
37	Ex vivo and in vivo evaluation of (2 <i>R</i> ,3 <i>R</i> )â€5â€{ <sup>18</sup> F]â€fluoroethoxy―and fluoropropoxyâ€benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse, 2007, 61, 962-970.	0.6	21
38	Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1297-1300.	1.0	12
39	Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2654-2657.	1.0	6
40	Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. Bioorganic and Medicinal Chemistry, 2006, 14, 1115-1125.	1.4	39
41	Synthesis and biological evaluation of a series of flavone derivatives as potential radioligands for imaging the multidrug resistance-associated protein 1 (ABCC1/MRP1). Bioorganic and Medicinal Chemistry, 2006, 14, 1599-1607.	1.4	43
42	Radiosynthesis of [18F]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 687-698.	0.5	21
43	Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. Bioorganic and Medicinal Chemistry, 2005, 13, 745-753.	1.4	38
44	Fragmentation pathway of dopamine transporter ligands: N-substituted-21²-carbomethoxy-31²-phenylnortropane derivatives. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 193-198.	1.4	2
45	Synthesis and Antiviral Activities of 3-Aralkyl-Thiomethylimidazo[1,2- <i>b</i> ]Pyridazine Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 177-182.	0.3	5
46	Substituted Diphenyl Sulfides as Selective Serotonin Transporter Ligands:  Synthesis and In Vitro Evaluation. Journal of Medicinal Chemistry, 2002, 45, 1253-1258.	2.9	33
47	Synthesis of Imidazo[2, 1-a]phthalazines, Potential Inhibitors of p38 MAP Kinase. Prediction of Binding Affinities of Protein Ligands. Archiv Der Pharmazie, 2002, 335, 7-14.	2.1	21
48	Influence of 2-Substituent on the Activity of Imidazo[1,2-a] Pyridine Derivatives Against Human Cytomegalovirus. Bioorganic and Medicinal Chemistry, 2002, 10, 941-946.	1.4	55
49	Synthesis of Imidazo[1,2-a]pyridines as Antiviral Agents. Journal of Medicinal Chemistry, 1998, 41, 5108-5112.	2.9	186
50	Synthesis and Pharmacological Evaluation in Mice of New Non-classical Antinociceptive Agents, 5-(4-Arylpiperazin-1-yl)-4-benzyl-1,2-oxazin-6-ones Chemical and Pharmaceutical Bulletin, 1997, 45, 659-667.	0.6	6
51	Solid-Supported Heterocumulenes:Â Preparation and Crystal Structure of Azaaplysinopsins. Journal of Organic Chemistry, 1997, 62, 4085-4087.	1.7	31
52	CONVERSION OF IMIDAZO[1,2-a]PYRIDINES INTO PYRIDO[1,2-e]PURINES. Heterocyclic Communications, 1996, 2, .	0.6	9
53	Thromboxane A2 biosynthesis inhibitors: Synthesis and evaluation of pyrazolotriazinyl alkanoic acids. Prostaglandins Leukotrienes and Essential Fatty Acids, 1994, 51, 157-161.	1.0	0
54	Synthetic Applicatons of 2-Aryl-4-piperidones. IX. Synthesis of Pyrido[1',2':1,2]imidazo[4,5-a]quinolizidin-2-one. Heterocycles, 1993, 36, 2451.	0.4	14

#	Article	IF	CITATIONS
55	Synthesis of new 2â€arylâ€3,3aâ€dihydroâ€4â€oxoâ€5 <i>H</i> â€pyrazoloâ€{1,5â€ <i>d</i> ][1,2,4]triazines ar derivatives. Journal of Heterocyclic Chemistry, 1991, 28, 769-772.	id some 1.4	of their